英夫利西单抗与阿达木单抗治疗克罗恩病:澳大利亚和新西兰观察性队列研究327例患者结果
该观察性队列研究纳入2007至2011年澳大利亚和新西兰连续327例符合抗TNFα治疗条件的克罗恩病患者(英夫利西单抗183例、阿达木单抗144例),比较两药疗效与安全性。结果显示各组应答率均为89%,两药维持应答相似;英夫利西单抗联用免疫调节剂者应答更持久且并发症更少;基线或前12个月使用糖皮质激素者疾病复发风险为未使用者的9至13倍。
要点
- 英夫利西单抗与阿达木单抗的应答率和维持应答相似,各组应答率均为89%。
- 英夫利西单抗需联用免疫调节剂才能达到与阿达木单抗单药治疗相当的维持应答。
- 基线或前12个月内使用糖皮质激素者维持治疗期间疾病复发风险为未使用者的9至13倍(P<0.0001)。
核心结论
- 在这项大型真实世界研究中,英夫利西单抗与阿达木单抗的应答特征相似,但英夫利西单抗需联用免疫调节剂才能达到与阿达木单抗单药治疗相当的维持应答。
研究设计与样本
- 观察性队列研究,纳入2007至2011年澳大利亚和新西兰连续327例符合抗TNFα治疗条件的克罗恩病患者,其中英夫利西单抗183例、阿达木单抗144例,前瞻性记录人口学和临床数据。
主要发现
- 所有组应答率均为89%,两药的中位维持应答相似。
- 英夫利西单抗联用免疫调节剂(而非阿达木单抗联用)显示总体应答显著更长(P=0.002),疾病和治疗相关并发症显著更少(P=0.017)。
- 基线时和/或前12个月内使用糖皮质激素者,维持治疗期间疾病复发的风险为未使用糖皮质激素者的9至13倍(P<0.0001)。
- 抗TNF初治和经治亚组的维持应答相似。
临床怎么用
- 英夫利西单抗需联用免疫调节剂以实现与阿达木单抗单药治疗相当的维持应答。
- 基线或前12个月内使用糖皮质激素与维持治疗期间疾病复发风险升高相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Maintenance anti-tumour necrosis factor-α (anti-TNFα) treatment for Crohn's disease is the standard of care for patients with an inadequate response to corticosteroids and immunomodulators. AIM: To compare the efficacy and safety of infliximab and adalimumab in clinical practice and assess the value of concomitant immunomodulator therapy. METHODS: We performed an observational cohort study in consecutive patients with Crohn's disease qualifying for anti-TNFα treatment in Australia and New Zealand between 2007 and 2011. Demographic and clinical data were prospectively recorded to identify independent factors associated with induction and maintenance of response to infliximab or adalimumab, or to either anti-TNFα therapy. RESULTS: Three hundred and twenty-seven patients (183 infliximab, 144 adalimumab) successfully applied for treatment. Eighty-nine percent responded in all groups and median maintenance of response was similar for the two agents. Concomitant immunomodulator with infliximab, but not adalimumab, demonstrated a significantly longer response overall (P = 0.002), and significantly fewer disease and treatment-related complications (P = 0.017). Corticosteroids at baseline, and/or in the preceding 12 months, were associated with a 9-13 times greater risk of disease flare during maintenance treatment as compared to no corticosteroids (P < 0.0001). Maintenance of response was similar in the anti-TNF naïve and anti-TNF experienced subgroups. CONCLUSIONS: In this large, real-life study, we demonstrate infliximab and adalimumab to have similar response characteristics. However, infliximab requires concomitant immunomodulator to achieve optimal maintenance of response comparable to adalimumab monotherapy. The results of this study will assist clinicians in further optimising patient care in their day-to-day clinical practice.
引用
- Doecke JD, Hartnell F, Bampton P, et al. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. Aliment Pharmacol Ther. 2016. PMID: 27995633. doi:10.1111/apt.13880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。